Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 1/2 2Phase 2 1

Status

Terminated 2

Sponsor Class

OTHER 2OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Kidney Neoplasms 1Castrate-resistant Prostate Cancer 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 155Carboplatin 147Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 119Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × dactolisib × Clear all
NCT01717898 2018-03-27

A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer

University of California, San Francisco

Phase 1/2 Terminated
6 enrolled 5 charts
Genitourinary

Castrate-resistant Prostate Cancer

NCT01453595 2016-02-29

BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)

Memorial Sloan Kettering Cancer Center

Phase 1/2 Terminated
10 enrolled 8 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡